Clinical Trial

A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

Name: A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma — clinical trial record (NCT07650266)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.

Trial Details

NCT Number	NCT07650266
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: Regeneron Pharmaceuticals
Conditions	Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
Enrollment	60 participants
Start Date	2026-09
Primary Completion	2030-07 (estimated)
Study Completion	2030-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-11